Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/NEUROGENE-INC-65218886/news/Neurogene-Presents-Favorable-Safety-Data-from-Phase-1-2-Trial-of-Ngn-401-Gene-Therapy-for-Rett-Syndr-46648479/?utm_source=whatsapp&utm_medium=social&utm_campaign=share